Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on April 15, 2026 reporting Item 8.01 (Other Events). FDA Fast Track designation granted to imdusiran for chronic hepatitis B.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA Fast Track designation granted to imdusiran for chronic hepatitis B
- Regulatory pathway may accelerate development and review for a serious condition with unmet medical need
- Milestone supports Arbutus’s hepatitis B program, but does not establish approval or efficacy.results
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.